Drug safety in the treatment of Crohn's disease.
The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by long-term maintenance therapy. The disease affects young patients and for this reason the long-term safety of the drugs needs to be especially taken into consideration. The safety, dose, duration for optimal efficacy and the most frequent adverse events will be described in this article.
Juillerat
Pascal
P
Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland.
Felley
Christian
C
Mottet
Christian
C
Froehlich
Florian
F
Vader
John-Paul
JP
Burnand
Bernard
B
Gonvers
Jean-Jacques
JJ
Michetti
Pierre
P
D000305:Adrenal Cortex Hormones / Q000592:standards / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000592:standards / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000592:standards / Q000627:therapeutic use*; D012307:Risk Factors; D012449:Safety
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents